Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ublituximab · Briumvi

Monoclonal antibody · Kills target cells, directed at CD20 (MS4A1) · developed by Tg Therapeutics

Approved FDA, Dec 2022
1 Registered trials

What is Ublituximab?

Ublituximab is a CD20-directed cytolytic monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes. Binding leads to B-cell lysis through antibody-dependent cellular cytolysis and complement-dependent cytolysis. It is studied in multiple sclerosis, including relapsing-remitting disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Briumvi
Drug type
Monoclonal antibody
Targets
CD20 (MS4A1)
Mechanism
Kills target cells, directed at CD20 (MS4A1)
Pathways
antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity
Therapy area
Neurology
Developer
Tg Therapeutics, Inc
In trials of
TGTX
FDA status
Approved as Briumvi (December 28, 2022), BLA761238 · FDA label
UNII
U59UGK3IPC

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 19, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07225361 Phase 4 Multiple Sclerosis Recruiting TGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting

Other drugs acting on MS4A1

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.